 MIAMI, June 21, 2021 GLOBE NEWSWIRE -- OPKO Health, Inc. NASDAQ: OPK today announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics Nicoya, for the development and commercialization in Greater China mainland China, Hong Kong, Macau and Taiwan of RAYALDEE for the treatment of secondary hyperparathyroidism SHPT in patients with stage 3 or 4 chronic kidney disease CKD. Nicoya is a leading biotechnology company incubated by 6 Dimensions Capital and its successor fund 120 Capital and other co-investors, and is focusing on the Greater China nephrology market. 